We’re reader-supported and may be paid when you visit links to partner sites. We don’t compare all products in the market, but we’re working on it!
Pharmaxis is a drug manufacturers-specialty & generic business based in Australia. Pharmaxis shares (PXS) are listed on the Australian Securities Exchange (ASX) and all prices are in Australian Dollars. Pharmaxis has a trailing 12-month revenue of around $28.3 million. If you're looking to buy shares, check out the steps below.
Our top pick for
US stocks
Our top pick for
ETF investing
Our top pick for
Overall broker
| 52-week range | $0.071 - $0.15 |
|---|---|
| 50-day moving average | $0.1089 |
| 200-day moving average | $0.1023 |
| Target price | $0.52 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-0.003 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Historical closes compared with the last close of A$0.105
| 1 week (2022-01-17) | 0.105 |
|---|---|
| 1 month (2021-12-24) | 0.105 |
| 3 months (2021-10-22) | -8.70% |
| 6 months (2021-07-23) | 19.32% |
| 1 year (2021-01-22) | 12.90% |
|---|---|
| 2 years (2020-01-24) | -16.00% |
| 3 years (2019-01-24) | -59.62% |
| 5 years (2017-01-24) | -61.82% |
Valuing Pharmaxis stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Pharmaxis 's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Pharmaxis 's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $2.4 million (£0.0 million).
The EBITDA is a measure of a Pharmaxis 's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $28.3 million |
|---|---|
| Gross profit TTM | $17.6 million |
| Return on assets TTM | -6.79% |
| Return on equity TTM | -178.87% |
| Profit margin | -4.13% |
| Book value | 0.003 |
| Market capitalisation | $60.4 million |
TTM: trailing 12 months
We're not expecting Pharmaxis to pay a dividend over the next 12 months.
Over the last 12 months, Pharmaxis 's shares have ranged in value from as little as $0.071 up to $0.15. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (AU average) beta is 1, while Pharmaxis 's is 0.5792. This would suggest that Pharmaxis 's shares are less volatile than average (for this exchange).
Pharmaxis Ltd engages in the research, development, and commercialization of healthcare products for the treatment of fibrotic and inflammatory diseases worldwide. The company operates through two segments, Mannitol Respiratory Business and New Drug Development. It offers Bronchitol, an inhaled dry powder for the treatment of cystic fibrosis; and Aridol, an airways inflammation test that is used to identify twitchy or hyper-responsive airways, as well as to assist in diagnosing and managing asthma. The company's product pipeline consists of amine oxidase inhibitors comprising semicarbazide-sensitive amine oxidase for diabetic retinopathy; selective lysyl oxidase like inhibitors targeting chronic fibrotic diseases, such as NASH, pulmonary fibrosis, kidney fibrosis, and cardiac fibrosis; and pan-lysyl oxidase inhibitors targeting myelofibrosis and other cancers, and scarring. It is also developing Orbital, a dry powder inhaler to deliver high drug doses to lungs. Pharmaxis Ltd was incorporated in 1998 and is headquartered in Frenchs Forest, Australia.
With the total market cap of the crypto sector dropping by a whopping 10% within the last few hours, it seems as though the coming few days could be highly volatile for ETH.
What are the things to watch out for when buying your child's first laptop?
As Russia gets ready to outlaw its local crypto market, BTC could be faced with even greater volatility in the near future.
Heavyweight stars Fancis Ngannou and Cyril Gane headline UFC 270.
Shares in Rio Tinto have climbed more than 15% in the last month.
Here are the 10 biggest movers on the ASX for Friday 21 January 2022.
This leave-in conditioner transformed my unwashed mop into silky locks that would make Rapunzel envious.
Samsung's next flagship S22 phone will be, in its own less than subtle phrasing, "noteworthy".
A fun superhero series, an epic sci-fi and a dark teen drama are among our top picks this week.
